Drug intelligence / Profile preview

Symprove

Development stage
Preclinical
Lead developer
Symprove
Modality
Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Symprove is a water-based, multi-strain probiotic food supplement designed to support the gut microbiome. It contains four unique strains of live and active bacteria: *Lacticaseibacillus rhamnosus* NCIMB 30174, *Lactobacillus plantarum* NCIMB 30173, *Lactobacillus acidophilus* NCIMB 30175, and *Enterococcus faecium* NCIMB 30176. [1, 2] These bacteria are delivered in a liquid solution containing an extract of germinated barley, which allows them to survive the acidic environment of the stomach and reach the gut alive. [2, 8] The proposed mechanism involves the probiotic bacteria modulating the gut microbiota, generating lactate, which in turn stimulates the growth of commensal bacteria and increases the production of short-chain fatty acids (SCFAs) like butyrate. This is believed to result in a mild anti-inflammatory effect, improved epithelial tight junction integrity, and faster wound healing in the gut lining. Symprove has been studied in clinical trials for its potential benefits in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), as well as irritable bowel syndrome (IBS) and Parkinson's disease. [24] The product is developed and manufactured by Symprove Ltd. [5, 26]

Brand names
Symprove
Other names
four-strain probioticmulti-strain probiotic
02

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on Symprove.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symprove.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call